28 March 2024 In progress. Please note that following on from advice received from the company this topic has now been scheduled back into the work programme. We now anticipate that the appraisal will ...

Tremelimumab has been approved by the FDA in the US for use in tandem with AZ's PD-L1 inhibitor Imfinzi (durvalumab) to treat adults with unresectable hepatocellular carcinoma (HCC), the most ...

AstraZeneca's anti-CTLA4 antibody tremelimumab is moving closer to what once looked like an extremely unlikely regulatory approval, after a string of negative trial results. The drugmaker said ...

The SMC has also has accepted Cladribine, also known as Mavenclad, for the treatment of relapsing-remitting multiple ...

Durvalumab (Imfinzi) is a PD-L1–blocking antibody that has 3 indications for non–small cell lung cancer (NSCLC). February ...

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is undergoing a significant transformation in its therapeutic and competitive landscape. Accounting for approximately 75% ...

Additionally, Imfinzi is approved as a perioperative treatment in combination with neoadjuvant chemotherapy in resectable NSCLC, and in combination with a short course of Imjudo (tremelimumab) and ...

This trial aims to evaluate whether treatment with durvalumab, alone or in combination with tremelimumab, plus particle therapy is a safe and synergistically effective treatment in patients with ...

(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Sebastien Hotte discussing a biomarker-selected phase II study of durvalumab and tremelimumab ...